This bill matters to voters because it directly addresses the persistent issue of high and rising prescription drug costs. Many Americans struggle to afford necessary medications, and drug price increases often outpace inflation and wage growth. By expanding drug inflation rebates to the commercial market, the bill aims to put downward pressure on drug prices for a larger segment of the population, including those with employer-sponsored or individual health plans.
If this bill becomes law, drug manufacturers would face stronger financial incentives to keep their price increases in check, as excessive increases would trigger mandatory rebate payments. The change in the base year to 2016 means that drug companies would be accountable for a longer period of price hikes, potentially leading to substantial savings for consumers and health plans. If the bill does not pass, drug price increases in the commercial market would likely continue without this specific inflation-based check, leaving consumers and private insurers to bear the full brunt of rising costs.
KEY PROVISIONS
5AI-extracted
PROVISION 01
Applies prescription drug inflation rebates to drugs covered by Medicare Part B that are also furnished in the commercial market.
This means drug companies would have to pay back money for excessive price increases on certain drugs, even if they are sold to people with private insurance.
PROVISION 02
Changes the base year for calculating Medicare Part B drug inflation rebates from 2021 to 2016.
This expands the period over which drug price increases are measured, potentially increasing the amount drug companies owe in rebates.
PROVISION 03
Applies prescription drug inflation rebates to drugs covered by Medicare Part D that are also furnished in the commercial market.
This extends inflation-based accountability for price increases to common pharmacy-dispensed drugs for a broader market.
PROVISION 04
Changes the base year for calculating Medicare Part D drug inflation rebates from 2021 to 2016.
This allows for the recovery of rebates based on price increases that occurred over a longer historical period for Part D drugs.
PROVISION 05
Sets effective dates for these changes: January 1, 2026, for Part B drugs and October 1, 2025, for Part D drugs.
These dates indicate when the new rebate calculation rules and expanded market application would begin to take effect.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
This bill matters to voters because it directly addresses the persistent issue of high and rising prescription drug costs. Many Americans struggle to afford necessary medications, and drug price increases often outpace inflation and wage growth. By expanding drug inflation rebates to the commercial market, the bill aims to put downward pressure on drug prices for a larger segment of the population, including those with employer-sponsored or individual health plans.
If this bill becomes law, drug manufacturers would face stronger financial incentives to keep their price increases in check, as excessive increases would trigger mandatory rebate payments. The change in the base year to 2016 means that drug companies would be accountable for a longer period of price hikes, potentially leading to substantial savings for consumers and health plans. If the bill does not pass, drug price increases in the commercial market would likely continue without this specific inflation-based check, leaving consumers and private insurers to bear the full brunt of rising costs.
KEY PROVISIONS
AI-extracted
high
Applies prescription drug inflation rebates to drugs covered by Medicare Part B that are also furnished in the commercial market.
This means drug companies would have to pay back money for excessive price increases on certain drugs, even if they are sold to people with private insurance.
high
Changes the base year for calculating Medicare Part B drug inflation rebates from 2021 to 2016.
This expands the period over which drug price increases are measured, potentially increasing the amount drug companies owe in rebates.
high
Applies prescription drug inflation rebates to drugs covered by Medicare Part D that are also furnished in the commercial market.
This extends inflation-based accountability for price increases to common pharmacy-dispensed drugs for a broader market.
high
Changes the base year for calculating Medicare Part D drug inflation rebates from 2021 to 2016.
This allows for the recovery of rebates based on price increases that occurred over a longer historical period for Part D drugs.
med
Sets effective dates for these changes: January 1, 2026, for Part B drugs and October 1, 2025, for Part D drugs.
These dates indicate when the new rebate calculation rules and expanded market application would begin to take effect.
Amendments for Medicare Part B drugs apply to calendar quarters beginning on or after this date.
October 1, 2025
Amendments for Medicare Part D drugs apply to applicable periods beginning on or after this date.
GLOSSARY
AI-written
Social Security Act, Title XVIII
The section of federal law that established and governs the Medicare program, which provides health insurance for Americans aged 65 or older, and younger people with certain disabilities.
Part B drugs
Drugs typically administered by a healthcare professional in a doctor's office, clinic, or hospital outpatient setting, often through infusion or injection.
Part D drugs
Prescription drugs that people typically pick up at a pharmacy, covered under Medicare's prescription drug benefit.
Prescription drug inflation rebates
Payments that drug manufacturers must make to the government (or in this bill, potentially to other payers) if the prices of their drugs increase faster than the rate of inflation.
Commercial market
Refers to healthcare services and prescription drugs paid for by private health insurance plans, such as those provided by employers or purchased individually, rather than by government programs like Medicare or Medicaid.
Base year
A specific starting year used as a reference point to measure changes over time, in this case, for calculating how much a drug's price has increased relative to inflation.
ACTION TIMELINE
2 EVENTS
APR 1, 25
Introduced in House
INTROREFERRAL
APR 1, 25
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
A standard measure for a drug, such as a pill, milligram, or vial, used to quantify drug dosage or volume for purposes of payment, pricing, and rebate calculations.
National Drug Code (NDC)
A unique, 10-digit, 3-segment number assigned to each specific drug product. It identifies the manufacturer, the drug's strength and dosage form, and its package size.
